Atossa Therapeutics, Inc. ATOS
1.93 USD -0.03 (-1.53%)
Regular-session close
1.93 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
1.86 Day range 2.09
1.70 52-week range 14.85
- YTD
- -78.19%
- 1 year
- -83.92%
News
benzinga.com Atossa Therapeutics Q3 EPS $(0.56) Beats $(0.90) Estimate Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.90) by 37.08 percent. This is a 60 percent decrease over losses of…
prnewswire.com Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other…benzinga.com Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19 Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of…
prnewswire.com Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapled Shares issued after…
prnewswire.com Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter CVRs entitle holders to 25% of net proceeds from monetization…
prnewswire.com Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying…
prnewswire.com Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways SEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.…
prnewswire.com Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other…
prnewswire.com Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib…
prnewswire.com Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July…
prnewswire.com Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.…
prnewswire.com Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.…
prnewswire.com Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations Trial-in-Progress Abstract Details Ongoing…
prnewswire.com Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20,…
seekingalpha.com Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
prnewswire.com Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026…
prnewswire.com Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other…
prnewswire.com Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer risk prevention candidate by marked reduction of mammographic breast density (MBD) Doses of both 1…
prnewswire.com Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- Atossa…
prnewswire.com Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other…
defenseworld.net Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) Critical Comparison Hyperfine (NASDAQ: HYPR - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two…
globenewswire.com The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Big money is moving back into biotech. Institutional investors have been writing some of the…
